<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842253</url>
  </required_header>
  <id_info>
    <org_study_id>72859</org_study_id>
    <nct_id>NCT04842253</nct_id>
  </id_info>
  <brief_title>HFNC vs LFNC in Patients With AF Undergoing RFCA Under Deep Sedation.</brief_title>
  <official_title>High Flow Nasal Cannula (HFNC) Versus Standard Low Flow Nasal Cannula (LFNC) in Patients With Atrial Fibrillation Undergoing Radiofrequency Catheter Ablation (RFCA) Under Deep Desaturation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxygen supplementation through high flow nasal cannula (HFNC) may reduce the incidence of&#xD;
      desaturation and hypoxemia during deep sedation at radiofrequency catheter ablation (RFCA&#xD;
      procedures).This study is designed to test the hypothesis that the incidence of hypoxemia and&#xD;
      desaturation in patients with atrial fibrillation undergoing RFCA under deep sedation, is&#xD;
      less when using HFNC as compared to use of standard low flow nasal cannula (LFNC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Desaturation may occur in patients under deep sedation which results in an elevated risk for&#xD;
      perioperative adverse events including hypoxemia (1-3). The incidence of hypoxemia was 168&#xD;
      per 1000 in a general procedural sedation and analgesia population (4). The clinical&#xD;
      significance of transient episodes of hypoxemia remains debatable. However, many&#xD;
      peri-operative incidents are often short-term and limited in nature, but a number of them are&#xD;
      a predictor to a serious complication with a permanent injury (5).This study investigates if&#xD;
      high flow nasal cannula (HFNC) as compared to low flow nasal cannula (LFNC) will result in a&#xD;
      lower incidence of intra-procedural oxygen desaturation and hypoxemia in patients with atrial&#xD;
      fibrillation undergoing deep sedation for radiofrequency catheter ablation (RFCA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypoxemia event</measure>
    <time_frame>The outcome variable will be measured during the patient's sedation.</time_frame>
    <description>The primary outcome measure will be the lowest measured blood oxygen level during the patient's sedation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of hypoxemia event</measure>
    <time_frame>The outcome variable will be measured during the patient's sedation.</time_frame>
    <description>The secondary outcome measure will be the duration of the lowest measured blood oxygen level during the patient's sedation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross over from oxygen therapy</measure>
    <time_frame>The outcome variable will be measured during the patient's sedation.</time_frame>
    <description>The secondary outcome measure will be cross over from oxygen therapy during sedation yes/no.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the incidence of hypoxemia and desaturation (SpO2 under 90% for &gt; 60 seconds).</measure>
    <time_frame>The outcome variable will be measured during the patient's sedation.</time_frame>
    <description>The secondary outcome measure will be the incidence SpO2 under 90% for &gt; 60 seconds.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Deep Sedation</condition>
  <condition>Oxygen Therapy</condition>
  <condition>Radiofrequency Ablation</condition>
  <arm_group>
    <arm_group_label>High flow nasal cannula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the high flow nasal cannula group will receive high flow nasal cannula oxygen during deep sedation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low flow nasal cannula</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in the current standard of care will receive low flow nasal cannula during deep sedation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High flow nasal cannula</intervention_name>
    <description>HFNC during deep sedation undergoing radiofrequency ablation for atrial fibrillation.</description>
    <arm_group_label>High flow nasal cannula</arm_group_label>
    <other_name>High flow nasal oxygen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults undergoing an elective RFCA for atrial fibrillation in the Maastricht UMC&#xD;
             Cardiac Catheter Labs under deep sedation administered by a clinician anesthesiology&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18 years&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 32 kg/mÂ²&#xD;
&#xD;
          -  Diagnosed Sleep Apnoea Syndrome (SAS)&#xD;
&#xD;
          -  Chronic Pulmonary Obstructive Disease (COPD) gold IV and COPD gold III with frequent&#xD;
             or recent exacerbation&#xD;
&#xD;
          -  Diagnosed pulmonary or cardiac condition requiring chronic oxygen therapy&#xD;
&#xD;
          -  Complete nasal obstruction&#xD;
&#xD;
          -  Active nose bleeding&#xD;
&#xD;
          -  Untreated pneumothorax (pre- existing)&#xD;
&#xD;
          -  Recent upper airway surgery&#xD;
&#xD;
          -  Recent base of skull fracture&#xD;
&#xD;
          -  Expected difficult airway&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang WF Buhre, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor Maastricht University. Key domain chair: Anesthesiologie.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marloes C Homberg, MPA</last_name>
    <phone>0031-43-3876543</phone>
    <phone_ext>5606</phone_ext>
    <email>marloes.homberg@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Esther AC Bouman, Doctor</last_name>
    <phone>0031-43-3876543</phone>
    <phone_ext>5606</phone_ext>
    <email>esther.bouman@mumc.nl</email>
  </overall_contact_backup>
  <reference>
    <citation>Jirapinyo P, Thompson CC. Sedation Challenges: Obesity and Sleep Apnea. Gastrointest Endosc Clin N Am. 2016 Jul;26(3):527-37. doi: 10.1016/j.giec.2016.03.001. Review.</citation>
    <PMID>27372775</PMID>
  </reference>
  <reference>
    <citation>Qadeer MA, Rocio Lopez A, Dumot JA, Vargo JJ. Risk factors for hypoxemia during ambulatory gastrointestinal endoscopy in ASA I-II patients. Dig Dis Sci. 2009 May;54(5):1035-40. doi: 10.1007/s10620-008-0452-2. Epub 2008 Nov 12.</citation>
    <PMID>19003534</PMID>
  </reference>
  <reference>
    <citation>Salukhe TV, Willems S, Drewitz I, Steven D, Hoffmann BA, Heitmann K, Rostock T. Propofol sedation administered by cardiologists without assisted ventilation for long cardiac interventions: an assessment of 1000 consecutive patients undergoing atrial fibrillation ablation. Europace. 2012 Mar;14(3):325-30. doi: 10.1093/europace/eur328. Epub 2011 Oct 23.</citation>
    <PMID>22024600</PMID>
  </reference>
  <reference>
    <citation>Conway A, Sutherland J. Depth of anaesthesia monitoring during procedural sedation and analgesia: A systematic review and meta-analysis. Int J Nurs Stud. 2016 Nov;63:201-212. doi: 10.1016/j.ijnurstu.2016.05.004. Epub 2016 May 25. Review.</citation>
    <PMID>27236824</PMID>
  </reference>
  <reference>
    <citation>Koers L, Eberl S, Cappon A, Bouwman A, Schlack W, Hermanides J, Preckel B. Safety of moderate-to-deep sedation performed by sedation practitioners: A national prospective observational study. Eur J Anaesthesiol. 2018 Sep;35(9):659-666. doi: 10.1097/EJA.0000000000000835.</citation>
    <PMID>29847362</PMID>
  </reference>
  <reference>
    <citation>Sago T, Watanabe K, Kawabata K, Shiiba S, Maki K, Watanabe S. A Nasal High-Flow System Prevents Upper Airway Obstruction and Hypoxia in Pediatric Dental Patients Under Intravenous Sedation. J Oral Maxillofac Surg. 2021 Mar;79(3):539-545. doi: 10.1016/j.joms.2020.10.018. Epub 2020 Oct 16.</citation>
    <PMID>33176129</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The plan to share IPD is still undecided because we are not certain if we are going to share all collected IPD or all IPD that underlie results in a publication.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

